Transcenta

Sep 15, 2020

Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy

Sep 07, 2020

Transcenta Holding Announces Appointment of Dr. Charlie Qi as Senior Vice President of Global Clinical Development

Aug 31, 2020

Transcenta Announces First Patient Dosed in Phase I China Trial of Claudin18.2 Targeting Monoclonal Antibody TST001

Jul 01, 2020

Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US

May 27, 2020

Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies

Apr 20, 2020

Transcenta Received IND Clearance from FDA for Initiating Clinical Trials for its Novel Humanized Claudin 18.2 Monoclonal Antibody TST001

Apr 01, 2020

908 Devices and Transcenta Expand Joint Innovation Partnership